Purchase this article with an account.
M. R. del Cid, M. A. Singer, D. J. Bell; Topical Nonsteroidal Therapy for Central Serous Retinopathy. Invest. Ophthalmol. Vis. Sci. 2010;51(13):3311.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To determine if topical nonsteroidal drops have a beneficial effect in treating central serous retinopathy.
A retrospective chart review was performed to identify patients diagnosed with central serous retinopathy who were prescribed topical nonsteroidal medications. Visual acuity and Stratus OCT data was collected.
Twelve eyes of 11 patients were included for analysis. Median visual acuity at initial presentation was 20/40 (range 20/20 to 20/150), and mean central foveal thickness was 444 microns (range 157 to 924 microns). Subsequent follow up visits and duration of medication use varied from 1 to 12 months. All 11 patients had improvement in vision with a median visual acuity of 20/30 (range 20/20 to 20/40) as measured on final follow up. All patients also demonstrated an improvement in mean foveal thickness, averaging 157 microns (range 130 to 198 microns) as measured on final follow up. Six of the 11 patients had significant improvement of vision (median 20/40 on initial presentation improving to 20/30) and central macular thickness (average 378 microns on initial presentation improving to 208 microns) after only one month of therapy. No adverse events were reported with the use of either nepafeanac or bromfenac at a dose of three to four times a day
Topical nonsteroidal medications were well tolerated and appeared to hasten visual recovery in central serous retinopathy. This therapeutic modality thus offers a potential treatment option for those with this disease. Prospective controlled trials are necessary on a larger scale to determine if therapy has an effect on rate of recurrence.
This PDF is available to Subscribers Only